Edition:
United States

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

1.60USD
16 Feb 2018
Change (% chg)

$0.10 (+6.67%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.60
Day's Low
$1.50
Volume
512
Avg. Vol
10,318
52-wk High
$2.95
52-wk Low
$1.25

Latest Key Developments (Source: Significant Developments)

Chiasma Announces Expected Year-End 2017 Cash And Investments Balance Of About $67 Mln
Monday, 8 Jan 2018 09:00am EST 

Jan 8 (Reuters) - Chiasma Inc ::CHIASMA INC - ANNOUNCES EXPECTED YEAR-END 2017 CASH AND INVESTMENTS BALANCE OF APPROXIMATELY $67 MILLION.CHIASMA-EXISTING CASH TO BE SUFFICIENT TO FUND OPERATIONS THROUGH ANTICIPATED RELEASE OF TOP-LINE DATA FROM CHIASMA OPTIMAL PHASE 3 TRIAL BY 2019 END.  Full Article

Chiasma Q3 loss per share $0.28
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Chiasma Inc ::Chiasma reports third quarter 2017 results.Q3 loss per share $0.28.Chiasma Inc - ‍ cash, cash equivalents & marketable securities as of Sept 30, 2017 were $73.2 million, compared with $93.0 million as of December 31, 2016​.  Full Article

Chiasma announces first patient is randomized in phase 3 trial of Octreotide capsules in patients with acromegaly
Wednesday, 27 Sep 2017 04:05pm EDT 

Sept 27 (Reuters) - Chiasma Inc :Chiasma announces first patient is randomized in phase 3 chiasma optimal clinical trial of Octreotide capsules in patients with acromegaly.Chiasma Inc - Meeting its previous guidance that enrollment in study would begin during second half of 2017​.Chiasma Inc - ‍Announced it has recently surpassed 50% patients randomized in its international phase 3 clinical trial​.  Full Article

Chiasma Q2 loss per share $0.28
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Chiasma Inc :Chiasma reports second quarter 2017 results.Q2 loss per share $0.28.Chiasma Inc - expect to have a cash and investment balance of at least $60 million at end of 2017.  Full Article

Chiasma reached deal with FDA on late-stage trial of its acromegaly drug
Thursday, 10 Aug 2017 04:00pm EDT 

Aug 10 (Reuters) - Chiasma Inc :Chiasma reaches agreement with FDA under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly.Chiasma reaches agreement with fda under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly.Chiasma Inc - ‍plans to initiate enrollment in new phase 3 clinical trial - optimal - during second half of 2017​.Chiasma Inc - ‍anticipates release of top-line data from new optimal trial by end of 2019​.Says "‍based on our current plans, we expect to have a cash and investment balance of at least $60 million at end of 2017"​.  Full Article

Chiasma reports Q1 loss per share $0.29
Friday, 5 May 2017 08:01am EDT 

May 5 (Reuters) - Chiasma Inc : :Chiasma reports first quarter 2017 results.Q1 loss per share $0.29.Chiasma Inc - following receipt of crl for octreotide capsules NDA, company participated in an end of review meeting with FDA.Chiasma Inc - FDA "reiterated its strong preference" for a randomized, double-blind and controlled trial for octreotide capsules.Chiasma Inc - for octreotide capsules, FDA suggested that some of its concerns could potentially be addressed through placebo-controlled study design.Chiasma Inc - FDA advised in CRL that, during a site inspection, certain deficiencies were conveyed to representative of one of Chiasma's suppliers.Chiasma Inc - in December 2016, supplier informed chiasma that it had received its establishment inspection report from FDA.Chiasma Inc - expects its existing cash, cash equivalents and marketable securities to fund operations beyond 2018.  Full Article

Chiasma Q4 loss per share $0.32
Thursday, 16 Mar 2017 04:05pm EDT 

Chiasma Inc : Chiasma reports fourth quarter and year end 2016 results . Q4 loss per share $0.32 .Chiasma Inc - for quarter ended december 31, 2016, net loss attributable to common stockholders was $7.9 million, or $0.32 per basic share..  Full Article

Chiasma names Mark J. Fitzpatrick as CEO
Friday, 30 Sep 2016 04:15pm EDT 

Chiasma Inc : Chiasma names Mark J. Fitzpatrick chief executive officer . Says CEO Mark Leuchtenberger resigned .Fitzpatrick currently serves as Chiasma's chief financial officer.  Full Article

Chiasma adopts a retention plan to provide cash retention payments to all remaining employees
Tuesday, 16 Aug 2016 09:59am EDT 

Chiasma Inc : Adopted a retention plan, effective immediately to provide cash retention payments to all remaining employees of co- sec filing . Retention payments are expected to be made in January 2017 Source: (http://bit.ly/2b1crqL) Further company coverage: [CHMA.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Chiasma announces workforce reduction
Tuesday, 16 Aug 2016 09:00am EDT 

Chiasma Inc : Chiasma announces workforce reduction . Continues to enroll patients in its mpowered phase 3 trial . Further reducing its workforce by approximately 44% . Will incur aggregate charges related to headcount reduction of about $0.8 million to $1.0 million for one-time severance and related costs in Q3 . Company expects to realize more than $7.0 million in annualized payroll and related expense savings as a result of restructuring actions . Chiasma Inc says expects to realize more than $7.0 million in annualized payroll and related expense savings as a result of these combined actions .Charges related to headcount reduction expected to result in cash expenditures that will be substantially complete by end of Q1 of 2017.  Full Article

BRIEF-Chiasma Announces Expected Year-End 2017 Cash And Investments Balance Of About $67 Mln

* CHIASMA INC - ANNOUNCES EXPECTED YEAR-END 2017 CASH AND INVESTMENTS BALANCE OF APPROXIMATELY $67 MILLION